AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Cosmo Pharmaceuticals (SIX Swiss: COSM) found itself this past week in the enviable position of attracting welcome attention from investors and other market watchers after
